title: Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.
abstract: Recent reports have shown gefitinib, epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) induced marked improvement in ECOG performance status (PS) as first-line therapy in EGFR mutation-positive patients with extremely poor PS. EGFR mutations frequently occur in east-Asian, female, non-smoking, adenocarcinoma patients, however they are occasionally detected in patients with non-adenocarcinomas or with a heavy smoking history. We describe a case in which EGFR mutation was detected in a male, current smoker, squamous cell carcinoma (SCC) patient with PS 4, who showed a marked response to the first-line gefitinib therapy. EGFR mutational analysis is recommended even for SCC patients especially in east-Asian populations.
authors.affiliation: Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Japan. kosuke624t@gmail.com
authors.forename: Kosuke
authors.initials: K
authors.lastname: Tanaka
authors.forename: Akito
authors.initials: A
authors.lastname: Hata
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kida
authors.forename: Reiko
authors.initials: R
authors.lastname: Kaji
authors.forename: Shiro
authors.initials: S
authors.lastname: Fujita
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Katakami
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Imai
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000532:radiotherapy / Q000556:secondary; D003131:Combined Modality Therapy; D000077143:Docetaxel; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D017809:Fatal Outcome; D000077156:Gefitinib; D018773:Genes, erbB-1; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D010166:Palliative Care; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D012907:Smoking / Q000009:adverse effects; D043823:Taxoids / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib